Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus MIDAZOLAM HYDROCHLORIDE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus MIDAZOLAM HYDROCHLORIDE AUTOINJECTOR.
CENTRAX vs MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Midazolam is a short-acting benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, enhancing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, amnestic, anticonvulsant, and muscle relaxant effects.
10-30 mg orally, 3-4 times daily.
10 mg intramuscularly once via autoinjector for acute seizure control.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life is 1.8–6.4 hours (mean ~3 hours) in healthy adults; prolonged in elderly, obese, hepatic impairment (up to 15–20 hours), and critical illness.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal excretion of metabolites (glucuronide conjugates) accounts for approximately 90% of elimination; less than 1% excreted unchanged; minimal fecal excretion (< 5%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine